PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University...
Dr. Arne Materna to join Ares Genetics as new Managing Director and CEO to lead Ares into next phase of...
TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the...
Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive...
Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour join POINT’s Board of Directors TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) --...
Strong Commercial Progress in India and the Middle East ·Versius has been adopted by a number of new hospitals, making...
Skylight Health will begin trading under new ticker “SHGFF” on the OTCQX December 9, 2020Company continues to trade under “SHG”...
- SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension...
Event will review the company’s novel approach to inducing fetal hemoglobin Live webcast on December 15, 2020 at 8:30am ET...
- Presentation taking place today, December 9, 2020 at 10:50 AM ET TORONTO and HOUSTON, Dec. 09, 2020 (GLOBE NEWSWIRE)...
Graphic 1 Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics,...
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company...
–Treatment with EDP1815 demonstrates statistically and clinically significant improvement in mean EASI and IGA* BSA scores––EDP1815 first-ever candidate targeting SINTAX™ to...
VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site...
COPENHAGEN, Denmark, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S, a clinical-stage AI-immunology company developing immunotherapies to improve the...
EIB signs €20 million (DKK 149 million) loan agreement with Danish research and development company Evaxion Biotech A/S.Evaxion will use financing for research...
Orphazyme A/SCompany announcement ...
Press release Malmö, Sweden December 9, 2020 Acarix announces the last patient included in Dan-NICAD II study After the inclusion...
The Company Exits Final Transitional Services Agreement and Announces the Consolidation of its North American Commercial Organizations PORTLAND, Maine--(BUSINESS WIRE)--Covetrus...
HydraFacial is a category-creating beauty health company that provides a platform and technology to a community of providers and consumers,...